Document is current
Any future updates will be listed below
-
Authors
Hsu, Chiun
Edeline, Julien
Masi, Gianluca
Ma, Yuk Ting
Wang, Weilin
Wege, Henning
Fei, Cong
Ling, Chen
Ma, Xiaopeng
Zhang, Pei
Huang, Ruiqi
Wu, Xikun
Shen, Zhirong
Li, Bai
Duque, Sandra Chica
Meng, Zhiqiang
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03419897 at ClinicalTrials.govnct03412773 at ClinicalTrials.govDocuments that mention this clinical trial
360 Tumor-immune signatures associated with response or resistance to tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)
https://doi.org/10.1136/jitc-2021-sitc2021.360
362 Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with clinical outcomes to tislelizumab monotherapy in patients with previously treated advanced hepatocellular carcinoma
https://doi.org/10.1136/jitc-2021-sitc2021.362
Documents that mention this clinical trial
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.
https://doi.org/10.1200/jco.2023.41.4_suppl.495
77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)
https://doi.org/10.1136/jitc-2020-sitc2020.0077
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).
https://doi.org/10.1200/jco.2023.41.16_suppl.4083
Long-term pooled safety analysis of tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers.
https://doi.org/10.1200/jco.2024.42.16_suppl.e14617
360 Tumor-immune signatures associated with response or resistance to tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)
https://doi.org/10.1136/jitc-2021-sitc2021.360
362 Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with clinical outcomes to tislelizumab monotherapy in patients with previously treated advanced hepatocellular carcinoma
https://doi.org/10.1136/jitc-2021-sitc2021.362
Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study
https://doi.org/10.1136/jitc-2021-003195
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.
https://doi.org/10.1200/go.2023.9.supplement_1.43
Immunotherapy for hepatocellular carcinoma: current status and future perspectives
https://doi.org/10.1136/esmoopen-2018-000455
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 European/North American (EU/NA) subgroup.
https://doi.org/10.1200/jco.2023.41.16_suppl.4082
